phone

Oncology Drugs Market Global Report 2017

  • Published Date: 17 Jul 2017
  • Number of Pages: 125
  • Category: Healthcare and Medical
  • Country: Global
Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market. Major competitors such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec are focusing on the R&D of new technologies such as next generation sequencing to develop MABs that are used for the development of chronic diseases such as cancer and other chronic diseases.

The Oncology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global oncology drugs sector.

Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:
Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Oncology Drugs Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.


Scope

Markets Covered: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)

Companies Mentioned: F. Hoffmann-La Roche Ltd, Novartis AG, Celgene, Johnson & Johnson, and Bristol-Myers Squibb Company

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Oncology Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Publisher Name : The Business Research Company
1. Oncology Drugs Market Characteristics;

2. Oncology Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Oncology Drugs Market Customer Information;

5. Oncology Drugs Market Segmentation;
5.1. Global Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 5.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Oncology Drugs Market Trends And Strategies;

6. Oncology Drugs Market Regional And Country Analysis;
6.1. Global Oncology Drugs Market, 2016, By Region; 6.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Oncology Drugs Market, 2016, By Country; 6.4. Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country

7. Global Oncology Drugs Market Comparison With Macro Economic Factors;
7.1. Oncology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Oncology Drugs Expenditure, Global;

8. Oncology Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Oncology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Oncology Drugs Expenditure, By Country;

9. Oncology Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Cancer, 2016, By Country;

10. Asia-Pacific Oncology Drugs Market;
10.1.1. Asia-Pacific Oncology Drugs Market Overview; 10.1.2. Asia-Pacific Oncology Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Oncology Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.2. Asia-Pacific Oncology Drugs Market: Country Analysis; 10.3. China Oncology Drugs Market; 10.3.1. China Oncology Drugs Market Overview; 10.3.2. China Oncology Drugs Historic Market, 2012 - 2016; 10.3.3. China Oncology Drugs Forecast Market, 2016 - 2020; 10.3.4. China Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.3.5. China Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.4. India Oncology Drugs Market; 10.4.1. India Oncology Drugs Market Overview; 10.4.2. India Oncology Drugs Historic Market, 2012 - 2016; 10.4.3. India Oncology Drugs Forecast Market, 2016 - 2020; 10.4.4. India Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.4.5. India Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.5. Japan Oncology Drugs Market; 10.5.1. Japan Oncology Drugs Market Overview; 10.5.2. Japan Oncology Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Oncology Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.5.5. Japan Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.6. Australia Oncology Drugs Market; 10.6.1. Australia Oncology Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Oncology Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.6.4. Australia Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;

11. Western Europe Oncology Drugs Market;
11.1.1. Western Europe Oncology Drugs Market Overview; 11.1.2. Western Europe Oncology Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Oncology Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.2. Western Europe Oncology Drugs Market: Country Analysis; 11.3. UK Oncology Drugs Market; 11.3.1. UK Oncology Drugs Market Overview; 11.3.2. UK Oncology Drugs Historic Market, 2012 - 2016; 11.3.3. UK Oncology Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.3.5. UK Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.4. Germany Oncology Drugs Market; 11.4.1. Germany Oncology Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Oncology Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.4.4 Germany Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.5 France Oncology Drugs Market; 11.5.1 France Oncology Drugs Historic Market, 2012 - 2016; 11.5.2 France Oncology Drugs Forecast Market, 2016 - 2020; 11.5.3 France Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.5.4 France Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.6. Italy Oncology Drugs Market; 11.6.2. Italy Oncology Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.6.4. Italy Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.7. Spain Oncology Drugs Market; 11.7.1. Spain Oncology Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Oncology Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.7.4. Spain Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;

12. Eastern Europe Oncology Drugs Market;
12.1.1. Eastern Europe Oncology Drugs Market Overview; 12.1.2. Eastern Europe Oncology Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Oncology Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.2. Eastern Europe Oncology Drugs Market: Country Analysis; 12.3. Russia Oncology Drugs Market; 12.3.1. Russia Oncology Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Oncology Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.3.4. Russia Oncology Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;

13. North America Oncology Drugs Market;
13.1.1. North America Oncology Drugs Market Overview; 13.1.2. North America Oncology Drugs Historic Market, 2012 - 2016; 13.1.3. North America Oncology Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.2. North America Oncology Drugs Market: Country Analysis; 13.3. USA Oncology Drugs Market; 13.3.1. USA Oncology Drugs Historic Market, 2012 - 2016; 13.3.2. USA Oncology Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.3.4. USA Oncology Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;

14. South America Oncology Drugs Market;
14.1.1. South America Oncology Drugs Market Overview; 14.1.2. South America Oncology Drugs Historic Market, 2012 - 2016; 14.1.3. South America Oncology Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.2. South America Oncology Drugs Market: Country Analysis; 14.3. Brazil Oncology Drugs Market; 14.3.1. Brazil Oncology Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Oncology Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.3.4. Brazil Oncology Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;

15. Middle East Oncology Drugs Market;
15.1.1. Middle East Oncology Drugs Market Overview; 15.1.2. Middle East Oncology Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Oncology Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);

16. Africa Oncology Drugs Market;
16.1.1. Africa Oncology Drugs Market Overview; 16.1.2. Africa Oncology Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Oncology Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);

17. Oncology Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. F. Hoffmann-La Roche Ltd; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Novartis Ag; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Celgene; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Johnson & Johnson; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Bristol-Myers Squibb Company 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Oncology Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market.

View Report

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors    Summary    In 2012, there were 32.6 million people living

View Report

Immuno-oncology is a unique approach that uses the bodys immune system to fight cancer. These therapies activate an individuals immune system, making it able to recognize cancer cells and destroy

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports